| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2010 | US7652039 Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis |
| 01/26/2010 | US7652038 Methods of reducing angiogenesis |
| 01/26/2010 | US7652037 Methods of lowering lipid levels in a mammal |
| 01/26/2010 | US7652036 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
| 01/26/2010 | US7652035 CRF receptor antagonists and methods relating thereto |
| 01/26/2010 | US7652034 Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
| 01/26/2010 | US7652033 HIF-1 inhibitors |
| 01/26/2010 | US7652032 5-Thioxylopyranose compounds |
| 01/26/2010 | US7652031 Compounds which mimic the chemical and biological properties of discodermolide |
| 01/26/2010 | US7652030 Acidic aqueous solution containing ipratropium and xylometazoline |
| 01/26/2010 | US7652029 Inhibiting cell growth including cancer such as leukemia, melanoma, cancer of non-small cell lung, colon , CNS, ovarian , renal , prostate , breast , and pancreas |
| 01/26/2010 | US7652028 Inflammatory disease, reperfusion injury, diabetes mellitus, reoxygenation injury resulting from organ transplantation, ischemia, neurodegenerative disease, renal failure, cardiovascular disease, cancer, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence |
| 01/26/2010 | US7652027 Phenanthroindolizidine alkaloids |
| 01/26/2010 | US7652026 Pharmaceutical composition |
| 01/26/2010 | US7652025 Remedies for sepsis |
| 01/26/2010 | US7652024 Obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction |
| 01/26/2010 | US7652023 Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine |
| 01/26/2010 | US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 01/26/2010 | US7652021 (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus |
| 01/26/2010 | US7652020 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction |
| 01/26/2010 | US7652019 5,6-trimethylenepyrimidin-4-one compounds |
| 01/26/2010 | US7652018 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas |
| 01/26/2010 | US7652017 Therapy for central nervous system, brain disorders |
| 01/26/2010 | US7652015 Kinase inhibitors |
| 01/26/2010 | US7652014 Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| 01/26/2010 | US7652013 Inhibitors of stearoyl-CoA desaturase |
| 01/26/2010 | US7652012 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof |
| 01/26/2010 | US7652011 Treating chronic neuropathic or inflammatory pain; [(1-methyl-1H-pyrrol-2-yl)methyl][[1-[(4-pyrazin-2-ylpiperazin-1-yl)acetyl]-4-[3-trifluoromethyl)phenyl]piperid-4-yl]methyl]amine |
| 01/26/2010 | US7652010 Azabicyclic aryl derivatives and their medical use |
| 01/26/2010 | US7652009 Substituted heterocycles and methods of use |
| 01/26/2010 | US7652008 Tricyclic benzopyran compound as anti-arrhythmic agents |
| 01/26/2010 | US7652007 Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments |
| 01/26/2010 | US7652006 Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof |
| 01/26/2010 | US7652005 Tricyclic δ-opioid modulators |
| 01/26/2010 | US7652004 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester |
| 01/26/2010 | US7652003 Macrocyclic β-secretase inhibitors |
| 01/26/2010 | US7652002 9-aminoacyl tetracycline compounds and methods of use thereof |
| 01/26/2010 | US7652001 Lipophilic, potentiated ester derivatives of nucleoside/viricide derivatives; side effect reduction; viricides; antiproliferative agents; bone metabolism disorders; antimetobolic, -tumor agents and -carcinogenic agents; poxviruses; herpes viruses; influenza and hepatitis viruses |
| 01/26/2010 | US7652000 Antibiotics incorporating borinic acid complexes; (bis(3-chloro-4-methylphenyl)boryloxy)(3-hydroxypyridin-2-yl)methanone; Antiinflammatory drugs; enhanced stability |
| 01/26/2010 | US7651999 2′, 5′-oligoadenylate analogs |
| 01/26/2010 | US7651998 administering a Venezuelan Equine Encephalitis (VEE) vector (alpha virus vector) comprising a heterologus nucleotide sequence to a subject; concurrently administering an antibody that specifically binds to the E1 and/or the E2 glycoprotein of the VEE vector to produce immune response to cancer patient |
| 01/26/2010 | US7651846 Treatment and diagnosis of conditions associated with elevated arginase activity |
| 01/26/2010 | US7651703 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 01/26/2010 | US7651700 Topical diclofenac patch |
| 01/26/2010 | US7651698 Prolonged release bioadhesive therapeutic systems |
| 01/26/2010 | US7651694 Encapsulated with macromolecules, bile salts |
| 01/26/2010 | US7651683 Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means |
| 01/26/2010 | US7651682 Polymerizable emulsions for tissue engineering |
| 01/26/2010 | US7651681 Method and compositions for in situ formation of protective and/or medicated films on body tissue |
| 01/26/2010 | US7650733 Method and apparatus for loading a container with a product |
| 01/26/2010 | CA2610818C Preparations containing pyridoxine and .alpha.-hydroxyisocaproic acid (hica) |
| 01/26/2010 | CA2555345C Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 01/26/2010 | CA2532437C N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto |
| 01/26/2010 | CA2505575C 17alpha-hydroxy-14beta-steroids with hormonal effect |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2471651C Amorphous substance of tricyclic triazolobenzazepine derivative |
| 01/26/2010 | CA2470064C Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 01/26/2010 | CA2469380C Heteroaryl-substituted aminocyclohexane derivatives |
| 01/26/2010 | CA2468748C Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 01/26/2010 | CA2465206C Polymeric thiol-linked prodrugs |
| 01/26/2010 | CA2456606C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2439685C Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations |
| 01/26/2010 | CA2434731C Modular infusion device and method |
| 01/26/2010 | CA2430579C Isoindolin-1-one glucokinase activators |
| 01/26/2010 | CA2426852C Formulation containing phosphate derivatives of electron transfer agents |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2408710C Compositions and methods for the treatment of colorectal cancer |
| 01/26/2010 | CA2403686C Substituted piperidines as melanocortin receptor agonists |
| 01/26/2010 | CA2396167C Isolation of carotenoid crystals |
| 01/26/2010 | CA2394188C Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/26/2010 | CA2393083C Use of hypoglycemic agent for treating impaired glucose metabolism |
| 01/26/2010 | CA2392630C 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties |
| 01/26/2010 | CA2390263C Method for producing metabolites from plants cultivated in soil-less medium |
| 01/26/2010 | CA2390029C Suspension comprising oxcarbazepine |
| 01/26/2010 | CA2385974C Treating endometriosis or infertility or improving fertility |
| 01/26/2010 | CA2383250C Phytochemicals for treatment of mastalgia and endometriosis |
| 01/26/2010 | CA2383027C Apparatus and method for anesthetizing the cervical region of a female |
| 01/26/2010 | CA2378370C 5-(e)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
| 01/26/2010 | CA2350031C N-arylsulfonylamino acid omega-amides |
| 01/26/2010 | CA2348928C Lps with reduced toxicity from genetically modified gram negative bacteria |
| 01/26/2010 | CA2346084C Benzothieno[3,2-c]pyridines as .alpha.2 antagonists |
| 01/26/2010 | CA2338854C Nitric esters and nitrate salts of specific drugs |
| 01/26/2010 | CA2336791C Preparation and use of sulfur-containing phosphonoformate derivatives and analogs |
| 01/26/2010 | CA2319255C Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy |
| 01/26/2010 | CA2303934C Tetrazole-containing rapamycin analogs with shortened half-lives |
| 01/26/2010 | CA2300407C 4-cyano-4-deformylsordarin derivatives |
| 01/26/2010 | CA2299470C Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| 01/26/2010 | CA2275345C Pro-drugs and counterparts of camptothecin, their application as medicines |
| 01/26/2010 | CA2270581C Aryloxypropanolamine derivatives, method of preparation and applications thereof |
| 01/26/2010 | CA2230086C Method to improve the biological and antiviral activity of protease inhibitors |
| 01/26/2010 | CA2219406C Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 01/26/2010 | CA2213567C Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor |
| 01/26/2010 | CA2188817C Angiogenesis inhibitor |
| 01/24/2010 | CA2638270A1 Therapeutic combination comprising an aurora kinase inhibitor and imatinib |
| 01/23/2010 | CA2636594A1 Regulatory compliant method to grow, harvest and produce industrial milled hemp seed and derivative functional products for human and veterinary use |
| 01/22/2010 | CA2677950A1 Stilbene-based compositions and methods of use therefor |
| 01/21/2010 | WO2010009474A1 Compositions and methods for treating osteoarthritis |
| 01/21/2010 | WO2010009453A1 Methods and systems for evaluating memory agents |